endpoints.news is our new home on June 1. endpts.com will still work, but the front door is now https://endpoints.news

Af­ter Bio­gen ex­it, Mit­subishi Tan­abe Phar­ma links up with Sal­ix to de­vel­op amise­limod; Two drug de­vel­op­ers set up ...

7 years ago
News Briefing

Gilead­'s selon­sert­ib fails PhI­II in less sick NASH pa­tients — to no one's sur­prise

7 years ago
R&D

Top 20 play­ers: Every­body loves an or­phan — es­pe­cial­ly when they come with block­buster sales and a long run of ...

7 years ago
Pharma
Cell/Gene Tx

As it takes Lartru­vo off the shelves, Lil­ly is set­ting up pro­gram to pro­vide drug ac­cess to cur­rent pa­tients

7 years ago
Pharma

Mar­tin Shkre­li gets a trans­fer to Brook­lyn fed­er­al prison in wake of his lat­est rule-break­ing es­capades be­hind bars

7 years ago
People

An­oth­er one of Bris­tol-My­er­s' PD-1/CT­LA-4 com­bo stud­ies bites the dust

7 years ago
R&D

US sen­a­tors, ac­tivists chas­tise Gilead­'s Tru­va­da pric­ing, spot­light­ing CDC patents on drug's use as HIV pre­ven­tion ...

7 years ago
Pharma

Whale watch­ing: What a decade of change at Big Phar­ma taught us about cor­po­rate phe­no­types

7 years ago
Deals
Biotech Voices

Tout­ing su­pe­ri­or nasal de­liv­ery, Sat­suma bags $62M for new for­mu­la­tion of old mi­graine drug

7 years ago
Financing

Good year, bad year? Two biotech CEOs hit pay dirt in 2018 as com­pen­sa­tion pack­ages swell

7 years ago
People

GSK plans $100M makeover of US man­u­fac­tur­ing site; La Jol­la Phar­ma gets a 'break­through' with late-stage drug

7 years ago
News Briefing

MD An­der­son tries to as­sure re­searchers in town hall meet­ing that Asian ‘eth­nic­i­ty’ is not the dri­ving force ...

7 years ago
China

In­censed by Chi­na CRISPR scan­dal, US con­sor­tium am­pli­fy glob­al call to sus­pend hu­man em­bryo edit­ing

7 years ago
R&D
Pharma

What does the past gen­er­a­tion of fail­ure in Alzheimer’s R&D look like in one slide?

7 years ago
R&D

Drug dis­trib­u­tor, for­mer ex­ecs charged for fu­el­ing opi­oid cri­sis as le­gal cam­paign widens its scope

7 years ago
Pharma

An 'oblig­a­tion to re­bound': Bio­gen backs fur­ther away from ad­u­canum­ab as R&D team hunts down late-stage M&A ...

7 years ago
R&D

No­var­tis CEO Narasimhan raids Glax­o­SmithK­line of­fices for his new San­doz chief

7 years ago
People

Anx­ious to fill Hu­mi­ra-sized rev­enue hole ahead of US patent cliff, Ab­b­Vie hits the ground run­ning with FDA ap­proval ...

7 years ago
R&D
Pharma

‘Chief blue­bird’ Nick Leschly nails a rich $24M com­pen­sa­tion boun­ty as biotech pack­ages soar

7 years ago
People

Te­va’s mi­graine drug can’t stop an­oth­er bad R&D headache as re­searchers scrap a failed PhI­II pro­gram for Ajovy

7 years ago
R&D
Pharma

Re­gen­eron's Schleifer: Amer­i­can pub­lic com­pa­nies should fund 'in­fra­struc­ture bank'; Sher­lock clos­es $49M round for ...

7 years ago
News Briefing

GSK punts a failed car­dio drug to a biotech start­up — which has a new de­vel­op­ment strat­e­gy in mind

7 years ago
Startups
R&D

Can dif­fer­ences in ge­nom­ic im­mune sys­tem sig­na­tures de­tect lung can­cer be­fore it takes hold?

7 years ago
Discovery

The biotech era in late-stage drug R&D and mar­ket­ing has ar­rived. And it looks like it’s here to stay

7 years ago
R&D
First page Previous page 948949950951952953954 Next page Last page
A service from the Financial Times